期刊
EXPERT REVIEW OF HEMATOLOGY
卷 11, 期 4, 页码 307-313出版社
TAYLOR & FRANCIS LTD
DOI: 10.1080/17474086.2018.1447378
关键词
Acute myeloid leukemia; biomarkers; stem cell transplantation; multiparametric flow-cytometry; RT-qPCR; prognosis
类别
资金
- Lazio Regional Agency for Transplantation and Related Diseases [971/E]
- Ministero dell'Istruzione, dell'Universita e della Ricerca [20110AX25X7]
- Associazione Italiana per la Ricerca sul Cancro [10555]
Introduction: Response to therapy is affected by the genetic heterogeneity of acute myeloid leukemia (AML) and persistence of leukemic cells below the threshold of morphological complete remission (mCR). Such persistence is called minimal (or measurable) residual disease (MRD).Areas covered: MRD assessment allows early identification of patients who are at high risk of relapse and who should timely receive aggressive therapy (e.g. allogeneic stem cell transplantation) and of those with a good quality mCR in whom an aggressive front-line therapy can be spared, avoiding the harm of excessive treatment toxicity. The most exploited methods to assess MRD are multiparameter flow cytometry (via identification of immunophenotypic aberrancies) or PCR-based assays (via identification of cytogenetic/molecular abnormalities).Expert commentary: A growing body of evidences demonstrates that positive MRD-testing at various time-points throughout the treatment course identifies patients at high risk of relapse. We will focus on the role of MRD as a biomarker to refine risk assessment and to prospectively direct treatment choices in adult with AML.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据